Our Approach

Recognizing that a truly effective monotherapy (or "silver bullet") is rare in medicine, Adamas was founded to approach drug development in an extremely practical way. Adamas first targets large market opportunities where combination therapy offers significant advantages over existing monotherapies. Adamas' platform allows the Company to identify, patent and develop novel drug combinations with mechanisms that work together in a complementary or synergistic manner and that can be can be optimized with improved pharmacokinetic (PK) profiles and strengths to achieve the clinical benefits characteristic of Adamas' proprietary, highly differentiated Advantaged Therapeutics.

Adamas scientists work with well-characterized and widely studied drugs, which helps reduce the uncertainties typically associated with the development of new chemical entities. The Company's resulting product candidates hold advantages in efficacy, tolerability and compliance over other offerings in their markets.

Back to top »